Humoral, Mucosal, and Cell-Mediated Immunity Against Vaccine and Nonvaccine Genotypes After Administration of Quadrivalent Human Papillomavirus Vaccine to HIV-Infected Children
| Autor: | William A. Meyer, Janine T. Bryan, Martha Brown, Myron J. Levin, Anna B. Moscicki, Adriana Weinberg, Lin-Ye Song, Alfred Saah, Pactg P Team |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
viruses Human Papilloma Virus Vaccine chemical and pharmacologic phenomena HIV Infections Alphapapillomavirus Cross Reactions Antibodies Viral Immunoglobulin G Major Articles and Brief Reports Immune system Immunity Humans Immunology and Allergy Cytotoxic T cell Medicine Papillomavirus Vaccines Child Immunity Mucosal Immunity Cellular biology business.industry Immunogenicity Vaccination virus diseases Virology CTL Infectious Diseases Immunology biology.protein Female Antibody business |
| Zdroj: | The Journal of Infectious Diseases. 206:1309-1318 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jis489 |
| Popis: | Objectives. To characterize the immunogenicity of a quadrivalent human papillomavirus vaccine (QHPV) in human immunodeficiency virus (HIV)–infected children, we studied their immune responses to 3 or 4 doses. Methods. HIV-infected children aged 7–12 years with a CD4 cell percentage of ≥15% of lymphocytes, received 3 doses of QHPV with or without a fourth dose after 72 weeks. Type-specific and cross-reactive antibodies and cell-mediated immunity were measured. Results. Type-specific antibodies to HPV6, 11, and 16 were detected in 100% and ≥94% of children at 4 and 72 weeks, respectively, after the third QHPV dose. Corresponding numbers for HPV18 were 97% and 76%, respectively. A fourth QHPV dose increased seropositivity to ≥96% for all vaccine genotypes. Four weeks after the third QHPV dose, 67% of vaccinees seroconverted to HPV31, an HPV16-related genotype not in the vaccine; 69% and 39% of vaccinees developed mucosal HPV16 and 18 immunoglobulin G antibodies, respectively; and 60% and 52% of vaccinees developed cytotoxic T lymphocytes (CTLs) for HPV16 and 31, respectively. Conclusions. Three QHPV doses generated robust and persistent antibodies to HPV6, 11, and 16 but comparatively weaker responses to HPV18. A fourth dose increased antibodies against all vaccine genotypes in an anamnestic fashion. CTLs and mucosal antibodies against vaccine genotypes, as well as cross-reactive antibodies and CTL against nonvaccine genotypes, were detected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|